Singapore, May 20 -- Agilent Technologies Inc. has announced a two-year research collaboration agreement with Singapore's Nucleic Acid Therapeutics Initiative (NATi), hosted by Agency for Science, Technology and Research (A*STAR), to accelerate research into complex oligonucleotide (oligo) candidates, a promising frontier in precision therapeutics with potential applications across cardiovascular-metabolic, rare and infectious diseases.

The global oligo therapeutics market exceeded $7 billion in 2025 and is projected to reach $18 billion by 2030, driven by clinically validated DNA- and RNA-based therapies that continue to face analytical challenges beyond liver-targeted delivery.

Under this agreement, the collaboration will focus on dev...